Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer ; volume:19 ; number:1 ; day:5 ; month:6 ; year:2017 ; pages:1-10 ; date:12.2017
Breast cancer research ; 19, Heft 1 (5.6.2017), 1-10, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Seachrist, Darcie D.
- Contributor
-
Sizemore, Steven T.
Johnson, Emhonta
Abdul-Karim, Fadi W.
Weber Bonk, Kristen L.
Keri, Ruth A.
SpringerLink (Online service)
- DOI
-
10.1186/s13058-017-0857-y
- URN
-
urn:nbn:de:1111-201710161711
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Seachrist, Darcie D.
- Sizemore, Steven T.
- Johnson, Emhonta
- Abdul-Karim, Fadi W.
- Weber Bonk, Kristen L.
- Keri, Ruth A.
- SpringerLink (Online service)
Other Objects (12)
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Appendicitis caused by the metastasis of HER2-positive breast cancer
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Appendicitis caused by the metastasis of HER2-positive breast cancer
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Appendicitis caused by the metastasis of HER2-positive breast cancer
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
How We Treat HER2-Positive Metastatic Breast Cancer
Nanotechnology approaches to addressing HER2-positive breast cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis